View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
March 3, 2022

Revealed: countries with most M&A deals in the pharma industry

Globally, the situation is looking distinctly positive for mergers and acquisitions in the pharma industry.

By Data Journalism Team

New figures released by GlobalData have shed light on the top locations for mergers and acquisitions in the pharmaceuticals industry.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Recent months have seen an uptick in M&A deals in Spain. The country has seen seven deals announced over the last two complete quarters, up from an average of two deals every six months between 2019 and 2021.

That’s the largest increase in M&A deal-making in the pharmaceuticals industry for any country.

The data shows that M&A activity is strongest in the US, which saw a total of 16 deals announced in the most recent quarter (2021 Q4). That’s down from 22 deals announced in the previous quarter (2021 Q3).

Despite being the global hotspot for M&A dealmaking in the pharma industry, the US has had a difficult few months, with just 29 deals announced in the last two complete quarters.

That’s a decrease compared the country’s average of 51 deals announced every six months between 2019 and 2021, and the sharpest decrease in M&A dealmaking in the pharmaceuticals industry experienced by any country in recent months.

The UK also performed well over the most recent quarter, with eight deals (up from zero in 2021 Q3).

Globally, the situation is looking distinctly positive for mergers and acquisitions in the pharma industry.

A total of 117 deals were announced in the last quarter, up from 81 deals in the previous quarter and from an average of 68 deals per quarter over the previous three years.

GlobalData tracks the performance and activities of more than 675,000 companies in over 200 countries around the world.

The data analytics firm's deals database includes the details of approximately one million deals, ranging from mergers and acquisition to venture capital financing, equity offerings and debt offerings.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena